Why did Wuxi PharmaTech acquire Huiyuan Bio?

Wuxi pharmatech acquired Huiyuan Bio and expanded its business map. WuXi PharmaTech announced the acquisition of HDBiosciences (HDB), a pre-clinical drug research and development outsourcing company. After the merger, Huiyuan Bio will become a wholly-owned subsidiary of Wuxi PharmaTech Group. Through this acquisition, Wuxi PharmaTech will further enhance its drug R&D capability from target verification to lead compound discovery and optimization, and improve and expand its integrated R&D service platform.